SPEAKER SERIES: Building a Biotech Company from Scratch: Challenges & Successes from startup to publicly traded company

OncoMed is a clinical development-stage company focused on first-in-class monoclonal antibody therapeutics targeting cancer stem cells. The company has formed strategic alliances with Celgene, Bayer and GSK and has raised approximately $622 million through venture capital and a 2013 IPO. John Lewicki, EVP, CSO and Founder of OncoMed, will speak about the company's journey from a 3 person startup to a public company with 110 employees.